91 - Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart

Thursday, October 17, 2024

11:18 AM – 11:30 AM US PT

Location: 411

Co-Author(s)

KN

Kristin Narayan, Ph.D.

Invivyd, Inc.
Waltham, Massachusetts, United States
Kathryn Mahoney, PharmD

Associate Director, Clinical Research
Invivyd, Inc.
Waltham, Massachusetts, United States
MW

Mark Wingertzahn, Ph.D.

Invivyd, Inc.
Waltham, Massachusetts, United States

Disclosure(s):

Myra Popejoy, Pharm.D.: Invivyd, Inc.: employee, Stocks/Bonds (Public Company)

Anna Holmes, PhD: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Chloe Katz, PMP: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Anne-Marie Phelan, MA: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Kazima Tosh, Ph.D.: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Yong Li, PhD: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Deepali Gupta, BSc: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Pamela Hawn, Pharm.D.: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Kristin Narayan, Ph.D.: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Kathryn Mahoney, PharmD: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Mark Wingertzahn, Ph.D.: Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)